Can pharmaceutical care decrease the oxidative stress in type 2 diabetes mellitus? - 04/02/24
Abstract |
Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder characterized by an increase in oxidative stress, which is itself related to development of T2D’s main chronic complications. Oxidative stress caused by elevated production of reactive species of oxygen and decrease of antioxidant defense system level, leads to activation of lipid peroxidation (LPO) and oxidative lipoprotein modification with increasing atherogenicity. Therefore, the aim of this study was to evaluate whether pharmacotherapeutic follow-up in patients with T2D, users and non-users of insulin, interferes with the levels of oxidative stress, measuring lipid peroxidation and protein oxidation, nitric oxide and superoxide dismutase levels. After the follow-up, there was a decrease in nitric oxide levels and an increase in superoxide dismutase concentration for the group with insulin therapy. Accordingly, these results show that the proposed pharmaceutical care program reduced the oxidative stress levels, mainly in patients in insulin therapy, as a consequence, can impact in the surging of the main chronic complications in T2D.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Proposed program improved medication adherence and reduced oxidative stress markers. |
• | Positive results can be attributed to adequate overall communication with patient. |
• | T2D patients on insulin therapy had worse metabolic control. |
• | Delay in administering insulin may be related to surging complications. |
Keywords : Pharmacotherapeutic follow-up, Oxidative stress, Nitric oxide, Superoxide dismutase
Plan
Vol 171
Article 116178- février 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?